A clinical-stage company aiming a femtosecond laser through the cornea to open a drainage channel thinner than a hair. No blade. No implant. Just light, guided by an image.
Picture a glaucoma clinic in 2026. A patient leans into a machine the size of a small desk. There is no scalpel tray, no incision, no implant being threaded into the eye. The physician looks at a high-definition image of structures a few hundred microns wide, lines up a target, and fires a femtosecond laser. In under a minute, a tiny channel has been opened inside the eye's natural drainage system. The patient sits up and goes home.
That clinic is the bet ViaLase, Inc. is making. The company is a venture-backed, clinical-stage medical technology business in Aliso Viejo, California, and it is building what it calls the first femtosecond laser designed to treat primary open-angle glaucoma. Its flagship is the ViaLuxe Laser System, and the procedure it performs has a deliberately on-the-nose name: FLigHT.
Glaucoma is the leading cause of irreversible blindness in the world. The mechanism is unglamorous: fluid inside the eye does not drain properly, pressure climbs, and the optic nerve quietly dies. The fix is to lower that pressure. The trouble is in how.
Door one is eye drops - cheap, but only if patients actually use them, every day, for the rest of their lives. Many don't. Door two is surgery, from laser trabeculoplasty to minimally invasive implants, which works but carries the friction of any procedure that physically enters the eye. Between a regimen people forget and a surgery people fear, there is a wide and uncomfortable gap.
ViaLase's argument is that the gap is a product opportunity. If you could lower pressure with the precision of surgery but the footprint of a quick in-office procedure - no incision, no hardware left behind - you would have something that fits where neither drops nor blades quite do.
ViaLase was founded in 2019 by Tibor Juhasz, PhD, and his resume is the whole pitch. Juhasz was part of the team that discovered the femtosecond laser could cut ocular tissue with micron-level precision without damaging the tissue around it - the science underneath modern bladeless LASIK. He went on to found IntraLase and then LenSx, two femtosecond laser companies that reshaped refractive and cataract surgery. He is also a professor of biomedical engineering and ophthalmology at UC Irvine.
So ViaLase is, in a sense, his third act with the same tool pointed at a new problem. The bet: a laser precise enough to reshape a cornea should be precise enough to open a channel in the trabecular meshwork - the eye's drainage filter - without ever entering the eye. In 2025 the company brought in Shawn O'Neil, a 30-year ophthalmic industry veteran, as CEO, with Juhasz moving to President and Chief Technology Officer and Pete England promoted to Chief Commercial Officer. The structure tells you the stage: founder on the technology, operator on the commercialization.
The ViaLuxe Laser System pairs a femtosecond laser with micron-level, high-definition imaging. The imaging is the quiet hero: it lets the physician see and target the trabecular meshwork - a structure thinner than a human hair, buried at the angle of the eye - with enough confidence to fire a laser at it. The laser then creates apertures through that meshwork, opening a path for fluid to drain and pressure to fall.
Combines a femtosecond laser with high-definition, micron-level image guidance to create drainage apertures through the trabecular meshwork in open-angle glaucoma patients.
Femtosecond Laser image-guided High-precision Trabeculotomy - a non-incisional, standalone procedure. The acronym is a wink at what it does with light.
The whole proposition rests on a word the medical device industry uses carefully: noninvasive. The laser does its work through the cornea. Nothing is cut open, nothing is implanted, nothing is left behind. That is the difference ViaLase is selling - and the reason regulators take their time.
Promises are cheap in medtech. Data is not. ViaLase's first-in-human study is the part that earns attention: across the 24-month protocol, the company reported no serious adverse events and a 34.6% reduction in intraocular pressure from baseline. For a treatment whose entire selling point is "precise but gentle," safety over two years is the number that matters most.
Then there is the regulatory scoreboard, which is harder to spin. In July 2024 ViaLase earned a CE Mark, clearing the ViaLase Laser to treat adult primary open-angle glaucoma in Europe. In the United States the bar is the FDA, and in December 2025 the company treated its first patient in an IDE clinical trial - a multicenter, randomized, controlled study designed with the FDA that pits the procedure against selective laser trabeculoplasty (SLT), today's standard in-office laser option.
The skeptic's footnote: none of this is FDA-cleared in the U.S. yet, and a trial that starts in December 2025 is years from a verdict. ViaLase is asking to be believed on a hypothesis backed by early data - which is exactly what clinical-stage means.
ViaLase describes its purpose as fueling the practice of noninvasive interventional glaucoma. Read that twice - it is naming a category that does not really exist on its own today, somewhere between the laser treatments doctors already do and the surgeries they would rather avoid. Building a product is hard. Building the slot it goes into is harder.
Ophthalmologists and glaucoma specialists - and, downstream, adult patients with primary open-angle glaucoma.
The trabecular meshwork: the eye's drainage filter, thinner than a human hair.
Lower eye pressure with the precision of surgery and the footprint of an in-office procedure.
Venture Investors Health Fund, Arboretum Ventures, and Falcon Vision, backed by KKR.
Return to the patient leaning into the machine. If ViaLase is right, the quiet thing that just happened - pressure lowered, optic nerve spared, no incision, no implant - becomes ordinary. Not a breakthrough you read about, but a Tuesday appointment. The whole point of redefining a treatment is that, eventually, nobody notices it was redefined.
That is still a hypothesis. A European clearance is real; a U.S. approval is not yet won. A 24-month safety record is promising; a decade of patients is not yet on the books. ViaLase is a small company, with a famous founder and a precise machine, asking the eye-care world to imagine a third door - and then walking through a clinical trial to prove the door opens.
No blade. No implant. Just light, aimed at something thinner than a hair - and a company patient enough to be measured.